Latest Reperfusion injury Stories
Fibrex Medical, a biopharmaceutical company focusing on cardiovascular and inflammatory diseases, today announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury - the damage to heart muscle that results from remedial treatment following a heart attack.
RegeneRx Biopharmaceuticals, Inc. (Amex:RGN) (www.regenerx.com) announced today that it received a second $100,000 award from the State of Maryland Industrial Partnerships (MIPS) program after successful completion of the first year's research goals.
NEW YORK (Reuters Health) - After resuscitation from cardiac arrest, there's a high risk of the patient dying from intractable shock, but this may be averted in some cases by a blood filtering procedure, according to a small study.
NEW YORK (Reuters Health) - Early restoration of blood flow to the heart after a heart attack saves lives in the short term and a new study shows that the early survival benefits associated with so-called reperfusion therapy last for at least 20 years and probably for the rest of a person's lifetime.
Post-acute myocardial infarction (AMI) syndrome was first described by Dressler in 1956.
- a slit in a tire to drain away surface water and improve traction.